Taken together, these results suggest that LO acts as an AGE inhibitor and alleviates AGE-triggered NAFLD by downregulating the MAPK/NF-κB expression. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.